Search for the New Molecular Targeted Therapies Based on Genetic Profiles of Ovarian Clear Cell Carcinoma
Project/Area Number |
25861473
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Multi-year Fund |
Research Field |
Obstetrics and gynecology
|
Research Institution | The University of Tokyo |
Principal Investigator |
UEHARA YURIKO 東京大学, 医学部附属病院, 登録研究医 (50648433)
|
Project Period (FY) |
2013-04-01 – 2016-03-31
|
Project Status |
Completed (Fiscal Year 2015)
|
Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2014: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2013: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
Keywords | 卵巣明細胞腺癌 / 染色体コピー数解析 / 遺伝子発現解析 / クラスター解析 / ARID1A / PIK3CA |
Outline of Final Research Achievements |
Among various histological subtypes of epithelial oarian cancer, ovarian clear cell carcinoma is generally chemoresistant and associated with poor clinical outcome even at an early stage. Therfore, biomarkers to predict the prognosis of clear cell carcinoma and the development of novel molecular tarfeted therapies, on the basis of these biomarkers, are warranted. In this study, we performed single nucleotide polymorphism analysis with clinical samples of ovarian cancer and evaluated the relationships between chromosomal instability and histological subtypes. Then, we performed microarray gene expression profiling and analyzed three subtypes defined with hierarchical clustering of the gene expression data. We further subclassified the clinical samples of clear cell carcinoma by gene expression profiling, and extracted the gene expression profiles and the signal pathway which might be associated with prognosis and chemoresistance of ovarian clear cell carcinoma.
|
Report
(4 results)
Research Products
(14 results)
-
-
[Journal Article] ntegrated copy number and expression analysis identifies profiles of whole-arm chromosomal alterations and subgroups with favorable outcome in ovarian clear cell carcinomas.2015
Author(s)
Uehara Y, Oda K, Ikeda Y, Koso T, Tsuji S, Yamamoto S, Asada K, Sone K, Kurikawa R, Makii C, Hagiwara O, Tanikawa M, Maeda D, Hasegawa K, Nakagawa S, Wada-Hiraike O, Kawana K, Fukayama M, Fujiwara K, Yano T, Osuga Y, Fujii T, Aburatani H.
-
Journal Title
PLoS One
Volume: 10
Issue: 6
Pages: e0128066-e0128066
DOI
Related Report
Peer Reviewed / Open Access / Acknowledgement Compliant
-
[Journal Article] Antitumor activity of a combination of dual PI3K/mTOR inhibitor SAR245409 and selective MEK1/2 inhibitor pimasertib in endometrial carcinomas.2015
Author(s)
Inaba K, Oda K, Ikeda Y, Sone K, Miyasaka A, Kashiyama T, Fukuda T, Uehara Y, Arimoto T, Kuramoto H, Wada-Hiraike O, Kawana K, Yano T, Osuga Y, Fujii T.
-
Journal Title
Gynecol Oncol.
Volume: 138(2)
Pages: 323-331
Related Report
Peer Reviewed / Acknowledgement Compliant
-
[Journal Article] PI3K/mTOR pathway inhibition overcomes radioresistance via suppression of the HIF1-α/VEGF pathway in endometrial cancer.2015
Author(s)
Miyasaka A, Oda K, Ikeda Y, Sone K, Fukuda T, Inaba K, Makii C, Enomoto A, Hosoya N, Tanikawa M, Uehara Y, Arimoto T, Kuramoto H, Wada-Hiraike O, Miyagawa K, Yano T, Kawana K, Osuga Y, Fujii T.
-
Journal Title
Gynecol Oncol.
Volume: 138(1)
Pages: 174-180
Related Report
Peer Reviewed / Acknowledgement Compliant
-
[Journal Article] Anti-tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells.2014
Author(s)
A. Miyasaka, K. Oda, Y. Ikeda, O. Wada-Hiraike, T. Kashiyama, A. Enomoto, N. Hosoya, T. Koso, T. Fukuda, K. Inaaba, K. Sone, Y. Uehara, R. Kurikawa, K. Nagasaka, Y.Matsumoto, T. Arimoto, S. Nakagawa, H. Kuramoto, K. Miyagawa, T. Yano, K. Kawana, Y. Osuga, T. Fujii.
-
Journal Title
BMC Cancer
Volume: -
Issue: 1
Pages: 179-179
DOI
Related Report
Peer Reviewed
-
-
-
[Presentation] Identification of genetic heterogeneity by whole exome sequencing using cell free DNA from blood samples.2015
Author(s)
Kayo Asada, Katsutoshi Oda, Kengo Gotoh, Reiko Kurikawa, Shogo Yamamoto, Kenji Tatsuno, Hiroki Ueda, Yuji Ikeda, Yuriko Uehara, Kenbun Sone, Osamu Hiraike-Wada, Kei Kawana, Tetsu Yano, Yutaka Osuga, Tomoyuki Fujii, Hiroyuki Aburatani
Organizer
AACR 106th Annual Meeting 2015
Place of Presentation
Philadelphia、USA
Year and Date
2015-04-18
Related Report
Int'l Joint Research
-
-
[Presentation] Anti-tumor effect of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in endometrial carcinoma cell lines2014
Author(s)
Aki Miyasaka, Katsutoshi Oda, Yuji Ikeda, Osamu Wada-Hiraike, Kenbun Sone, Yuriko Uehara, Yoko Matsumoto, Takahide Arimoto, Shunsuke Nakagawa, Hiroyuki Kuramoto, Tetsu Yano, Kei Kawana, Yutaka Osuga, Tomoyuki Fujii
Organizer
2014 AACR annual meeting
Place of Presentation
San Diego, California
Year and Date
2014-04-05 – 2014-04-09
Related Report
-
-
[Presentation] Comparison of genomic alteration patterns between ovarian clear cell carcinoma and renal cell carcinoma2013
Author(s)
Kayo Asada, Takahiro Koso, Katsutoshi Oda, Yuriko Uehara, Shogo Yamamoto, Kenji Tatsuno, Hiroki Ueda, Yuji Ikeda, Osamu Hiraike,Kei Kawana, Tetsu Yano, Tomoyuki Fujii, Hiroyuki Aburatani
Organizer
第72回日本癌学会学術総会
Place of Presentation
横浜
Related Report
-
-